Completed PHASE2 INTERVENTIONAL 2-arm NCT01893125

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy

A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy

Sponsor: Convergence Pharmaceuticals

Conditions Diabetic Peripheral Neuropathy

Interventions CNV2197944 Placebo

Updated 6 times since 2017 Last updated: Oct 29, 2014 Started: Aug 31, 2013 Primary completion: Jun 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01893125, this PHASE2 trial focuses on Diabetic Peripheral Neuropathy and remains completed. Sponsored by Convergence Pharmaceuticals, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Convergence Pharmaceuticals

Data source: Convergence Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Győr, Hungary